International product information

The product details shown after you switch describe the versions of Rho authorized outside the United States, including the Rho Score, which is not part of the US version.

US product information

The product details shown after you switch describe the version of Rho authorized in the United States, which reports whether a patient is Rho Positive.

Request a demo →
← All news
Funding and awards

Amgen Canada funds the proof-of-concept study behind Rho

Toronto. 16 Bit received $150,000 from Amgen Canada to develop machine learning for osteoporosis screening and fracture risk prediction, using the Canadian Multicentre Osteoporosis Study cohort of 6,539 women and 2,884 men. The work showed that bone mineral density could be estimated from a conventional X-ray, and became Rho.

The Canadian Multicentre Osteoporosis Study (CaMos) followed participants across Canada for more than two decades, with DXA measurements and fracture outcomes. Pairing its X-rays with its DXA results made it possible to test whether a neural network could learn bone density from a standard radiograph.

The funding amount is 16 Bit’s own figure. Amgen’s collaboration continued in the prospective Sunnybrook study registered in 2022 and published in 2025.